Search results for "Proton-pump inhibitor"

showing 10 items of 22 documents

Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease.

2009

Introduction: Functional dyspepsia and non-erosive reflux disease (NERD) are prevalent gastrointestinal conditions with accumulating evidence regarding an overlap between the two. Still, patients with NERD represent a very heterogeneous group and limited data on dyspeptic symptoms in various subgroups of NERD are available. Aim: To evaluate the prevalence of dyspeptic symptoms in patients with NERD subclassified by using 24 h impedance-pH monitoring (MII-pH). Methods: Patients with typical reflux symptoms and normal endoscopy underwent impedance-pH monitoring off proton pump inhibitor treatment. Oesophageal acid exposure time (AET), type of acid and non-acid reflux episodes, and symptom ass…

AdultMalemedicine.medical_specialtyEsophageal pH MonitoringAdolescentNerdmedicine.drug_classProton-pump inhibitorGastroenterologyBody Mass IndexDiagnosis DifferentialYoung AdultEsophagusSex FactorsHeartburnInternal medicinemedicineElectric ImpedanceHumansNERD FD FH SAP1506EsophagusDyspepsiaAgedAnalysis of Variancemedicine.diagnostic_testbusiness.industryEsophageal diseaseStomachdigestive oral and skin physiologyStomachGastroenterologyRefluxHeartburnMiddle Agedmedicine.diseasedigestive system diseasesOesophagusmedicine.anatomical_structureGastroesophageal RefluxFemaleEsophagoscopymedicine.symptombusinessEsophageal pH monitoring
researchProduct

Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses o…

2011

Abstract Background Prescription of non-steroidal anti-inflammatory drugs (NSAIDs) should be based on the assessment of both gastrointestinal (GI) and cardiovascular (CV) risk for the individual patient. We aimed to assess the GI/CV risk profile and the pharmacological management of patients with osteoarthritis (OA) in clinical practice. Methods We conducted a cross-sectional, multicentre, observational study of consecutive OA patients that visited 1,760 doctors throughout the Spanish National Health System (NHS) in a single day. The presence of GI risk factors, CV histories, hypertension and current pharmacological treatments was recorded. Results Of the 60,868 patients, 17,105 had a diagn…

AdultMalemedicine.medical_specialtymedicine.drug_classGastrointestinal DiseasesPopulationProton-pump inhibitorlcsh:MedicineOsteoarthritisRisk AssessmentInternal medicineOsteoarthritisMedicineHumansProspective StudiesRisk factorMedical diagnosisMedical prescriptioneducationAgedAged 80 and overMedicine(all)education.field_of_studyCardiovascular Historybusiness.industrylcsh:RAnti-Inflammatory Agents Non-SteroidalGeneral MedicineMiddle Agedmedicine.diseaseDrug UtilizationCross-Sectional StudiesPrescriptionsCardiovascular DiseasesSpainPhysical therapyObservational studyFemaleGuideline AdherencebusinessResearch ArticleBMC Medicine
researchProduct

Effect of intravenous application of esomeprazole 40???mg versus pantoprazole 40???mg on 24-hour intragastric pH in healthy adults

2007

BACKGROUND: It has been demonstrated that therapy with proton pump inhibitors reduces recurrence of bleeding following initial endoscopic treatment of bleeding peptic ulcers. AIM: This study compared the effects of esomeprazole 40 mg and pantoprazole 40 mg on intragastric acid control. Both substances were administered intravenously as 15-min infusion and as bolus injection. METHODS: Healthy men and women volunteers were enrolled in this single-center, open, randomized, three-way crossover study. After administration of esomeprazole 40 mg and pantoprazole 40 mg intravenously as 15-min infusion, and pantoprazole 40 mg intravenously as bolus injection, continuous 24-h intragastric pH monitori…

AdultMalemedicine.medical_specialtymedicine.drug_classPepticProton-pump inhibitorPharmacologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesHelicobacter InfectionsEsomeprazoleGastric AcidInternal medicineHumansMedicineEsomeprazole SodiumInfusions IntravenousPantoprazoleMonitoring PhysiologicPantoprazoleCross-Over StudiesHelicobacter pyloriHepatologybusiness.industryStomachGastroenterologyEsomeprazoleGastric Acidity DeterminationHydrogen-Ion ConcentrationMiddle AgedAnti-Ulcer AgentsCrossover studymedicine.anatomical_structureInjections IntravenousBody ConstitutionGastric acidFemalebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients.

1996

BACKGROUND: The combination of omeprazole with amoxycillin or clarithromycin is used as treatment against Helicobacter pylori. It seems likely that the antibacterial activity of the antibiotic may be improved by increasing gastric pH towards neutrality, and a twice daily regimen of omeprazole is probably needed. AIM: To assess the effects of twice daily administration of omeprazole 20 and 40 mg. METHODS: Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08.00 and 20.00 h). On the sixth day of dosing they underwent 24-h gastric pH-metry. RESULTS: Omeprazole 20 and 40 mg b.d. produce…

AdultMalemedicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyHelicobacter InfectionsGastric AcidInternal medicineClarithromycinmedicineHumansSingle-Blind MethodPharmacology (medical)Enzyme InhibitorsOmeprazoleGastric Acidity DeterminationCross-Over StudiesHelicobacter pyloriHepatologybiologybusiness.industryStomachGastroenterologyProton Pump InhibitorsGastric Acidity DeterminationMiddle AgedHelicobacter pyloribiology.organism_classificationCrossover studyCircadian Rhythmmedicine.anatomical_structureDuodenal UlcerDuodenumFemalebusinessOmeprazolemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding

2003

Abstract Background. The reliability of the rapid urease test has not been proven in patients with peptic ulcer bleeding. Some studies show bad diagnostic results with the rapid urease test for gastrointestinal bleeding. Aims. To evaluate the efficacy of the rapid urease test in patients with bleeding gastric or duodenal ulcers. Patients and methods. A total of 96 patients with acute peptic ulcer bleeding without proton pump inhibitor or antibiotic therapy within the last 14 days before bleeding were included into the study. During index endoscopy, specimens for histological and rapid urease test were obtained from the antrum and corpus mucosa of the stomach. Patients were also investigated…

Breath testmedicine.medical_specialtyGastrointestinal bleedingHepatologymedicine.diagnostic_testbiologymedicine.drug_classbusiness.industryStomachFalse Negative ReactionsGastroenterologyRapid urease testProton-pump inhibitorHelicobacter pyloribiology.organism_classificationmedicine.diseaseGastroenterologydigestive system diseasesmedicine.anatomical_structurePredictive value of testsInternal medicinemedicinebusinessDigestive and Liver Disease
researchProduct

Effect of gastric acid suppression on 13 C-urea breath test: comparison of ranitidine with omeprazole

2000

Background: The assessment of the effect of H2 antagonists on the results of the urea breath test has produced controversial results. Aim: To assess whether standard doses of both omeprazole and H2 blockers can adversely influence the accuracy of the urea breath test. Methods: Sixty dyspeptic patients with ascertained Helicobacter pylori infection were recruited for this prospective, open study. They were randomized to receive either omeprazole 20 mg at 08:00 hours (n = 30) or ranitidine 300 mg at 22:00 hours (n = 30) for 14 days. The urea breath test was performed at baseline, on day 14, while patients were still taking the antisecretory drugs, and on day 21, 1 week after their cessation. …

Breath testmedicine.medical_specialtyHepatologybiologymedicine.diagnostic_testbusiness.industrymedicine.drug_classUrea breath testGastroenterologyProton-pump inhibitorHelicobacter pyloribiology.organism_classificationGastroenterologySurgeryRanitidineInternal medicineMedicineIngestionPharmacology (medical)businessAdverse effectOmeprazolemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer

1998

Background It is now clear that the extent to which gastric acid secretion must be suppressed varies with the clinical condition being treated. Aim To assess the 24-h control of gastric acidity and the individual response variability of three different doses of pantoprazole. Methods Sixty-four duodenal ulcer patients were recruited for this prospective, randomized, multicentre, double-blind, parallel-group study. They were subdivided into three well-matched groups treated with 20 mg o.m., 40 mg o.m. and 40 mg b.d. of pantoprazole, respectively. Endoscopy and intragastric pH monitoring were performed in each patient before and after 14 days of treatment. Results Fifty-five patients were elig…

Gastric Acidity Determinationmedicine.medical_specialtyChemotherapyHepatologyDosebusiness.industrymedicine.drug_classStomachmedicine.medical_treatmentGastroenterologyProton-pump inhibitorGastroenterologymedicine.anatomical_structurePharmacodynamicsInternal medicinemedicineGastric acidPharmacology (medical)businessPantoprazolemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply

2021

Liver CirrhosisMaleHepatologymedicine.drug_classbusiness.industryGastroenterologyProton-pump inhibitorProton Pump InhibitorsBone fracturemedicine.diseaseBioinformaticsFractures BonemedicineHumansPharmacology (medical)Point (geometry)businessAlimentary Pharmacology & Therapeutics
researchProduct

Methotrexate induced sprue-like syndrome

2008

A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate. He did not respond to treatment with oral iron not a proton pump inhibitor and an upper endoscopy was performed. The histological study of the duodenal biopsies showed villus atrophy. After removing the methotrexate, administrating intramuscular iron and undertaking a gluten-free diet, the histological and analytical alterations progressively resolved.

MalePathologymedicine.medical_specialtyDuodenummedicine.drug_classBiopsyProton-pump inhibitorCase ReportEndoscopy GastrointestinalSprueAtrophyBiopsymedicineHumansSpondylitis AnkylosingSpondylitisAnkylosing spondylitismedicine.diagnostic_testbusiness.industryGastroenterologySyndromeGeneral MedicineMiddle Agedmedicine.diseaseCeliac DiseaseMethotrexateIron-deficiency anemiaAntirheumatic AgentsMethotrexateAtrophybusinessmedicine.drugWorld Journal of Gastroenterology
researchProduct